Académique Documents
Professionnel Documents
Culture Documents
http://www.chemotherapyadvisor.com/bone-cancer-treatment-regimens/art...
Home Cancer Types Bone Cancer Brain Cancer Breast Cancer Endocrine Cancer Gastrointestinal Cancer Genitourinary Cancer Gynecologic Cancer Head and Neck Cancer Hematologic Cancers Lung Cancer Sarcoma Skin Cancer Regimens Bone Cancer Brain Cancer Breast Cancer Endocrine Cancer Gastrointestinal Cancer Genitourinary Cancer Gynecologic Cancer Head and Neck Cancer Hematologic Cancers Lung Cancer Other Cancers Rare Cancers Skin Cancer Clinical Trials News Latest News General Oncology News Conference Coverage General Medical News Conference Calendar Features Features From the Advisory Board Cases
1 of 13
9/7/2012 10:15 PM
http://www.chemotherapyadvisor.com/bone-cancer-treatment-regimens/art...
CME CME Articles myCME.com Resources Oncology Nurse Advisor Clinical Charts Medical Calculators Useful Links Treatment Guidelines Patient Fact Sheets Video Newsletter Archives Pharma Resource Center Research Library Supportive Care Pain Management Palliative Care Side Effect Management Blogs The Expert Blog The Advisor Blog Submissions Slideshows FIND DRUGS: BRAND NAME GENERIC NAME INDICATION MANUFACTURERS COMPARE DRUGS RSS | Log out | My Account Chemotherapy Advisor > Cancer Treatment Regimens > Bone Cancer Treatment Regimens
Tweet Like
0 1
2 of 13
9/7/2012 10:15 PM
http://www.chemotherapyadvisor.com/bone-cancer-treatment-regimens/art...
The selection, dosing, and administration of anticancer agents and the management of associated toxicities are complex. Drug dose modifications and schedule and initiation of supportive care interventions are often necessary because of expected toxicities and because of individual patient variability, prior treatment, and comorbidities. Thus, the optimal delivery of anticancer agents requires a healthcare delivery team experienced in the use of such agents and the management of associated toxicities in patients with cancer. The cancer treatment regimens below may include both FDA-approved and unapproved uses/regimens and are provided as references only to the latest treatment strategies. Clinicians must choose and verify treatment options based on the individual patient. NOTE: Grey shaded boxes contain updated regimens.
Chemotherapy for Ewing's sarcoma and osteosarcoma should include growth factor support. Conventional chondrosarcoma has no known standard chemotherapy options. Mesenchymal chondrosarcoma: follow Ewing's sarcoma regimens. Malignant fibrous histiocytoma (MFH) of bone: follow osteosarcoma regimens.
REGIMEN
DOSING
3 of 13
9/7/2012 10:15 PM